Identification of a novel necroptosis-related lncRNA-based prognostic model and immunological characteristics of Lung Adenocarcinoma

Peng Xia,Degui Wang,Rong Shen,Zhao Guo,Siwei Ouyang,Xuguang Yang,Xiangwen Liu,Kun Xie
DOI: https://doi.org/10.21203/rs.3.rs-1601242/v1
2022-01-01
Abstract:Abstract Lung adenocarcinoma (LUAD) is one of the most common pathological types of lung malignant tumor with high morbidity and mortality. LncRNAs are gradually recognized to play crucial roles in tumor occurrence and development. Necroptosis is a newly established way for cell programmed death, undertaking essential roles in anti-tumor. Therefore, identifying necroptosis-related lncRNAs and based on them to evaluate the signatures of LUAD is essential for patients’ survival prediction and therapy. This study identified 41 lncRNAs related to LUAD patients’ prognosis and necroptosis from The Cancer Genome Atlas (TCGA). Particularly, a 13-lncRNAs (LINC02693, FGD5-AS1, TMPO-AS1, LINC01116, LINC02802, RHOQ-AS1, LINC02273, LINC01800, LINC00996, CADM3-AS1, SFTA3, CRNDE, PARP11-AS1) prognostic model was constructed via LASSO regression based on these 41 lncRNAs. The model’s prediction accuracy was evaluated by receiver operating characteristic (ROC) and independent-prognosis analysis; besides, a Gene Expression Omnibus (GEO) dataset was applied for external validation. In addition, we also implemented a consensus clustering analysis based on the 41 genes to separate LUAD patients into two subgroups. We compared the features of subgroups in multiple dimensions, including survival, immune microenvironment, immune cells infiltration, and gene co-expression network analysis. Based on this study, we established a prognosis necroptosis-related risk model to predict LUAD patients’ prognosis and systematically understood the correlation between immune and necroptosis. This study can applicate in clinical to predict the prognosis of LUAD patients and provide new insight into LUAD immune therapy.
What problem does this paper attempt to address?